Diagnostics for latent TB infection: Incremental, not transformative progress

European Respiratory Journal

Volumn 47, Issue 3, 2016, Pages 704-706

  Pai, Madhukar ^a   Sotgiu, Giovanni ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN DETECTION; ANTIGEN SPECIFICITY; EDITORIAL; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING; TUBERCULIN TEST; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION; COMMUNICABLE DISEASE;

COMMUNICABLE DISEASES; HUMANS; LATENT TUBERCULOSIS; TUBERCULIN TEST;

EID: 84959860350     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01910-2015     Document Type: Editorial

References (18)

1. World Health Organization. The End TB Strategy. Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015. www.who.int/tb/post2015-TBstrategy.pdf?ua=1 Date last accessed: April 7, 2015. Date last updated: November 2015.
2. World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva, WHO, 2014.
3. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563-1576.
4. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-1204.
5. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014; 27: 3-20.
6. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: 761-776.
7. Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100-111.
8. Barry CE III, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-855.
9. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
10. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45-55.
11. Aggerbeck H, Giemza R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS One 2013; 8: e64215.
12. Bergstedt W, Tingskov PN, Thierry-Carstensen B, et al. First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. PLoS One 2010; 5: e11277.
13. Kiselev VI, Baranovskii PM, Rudykh IV, et al. [Clinical trials of the new skin test Diaskintest for the diagnosis of tuberculosis]. Problemy tuberkuleza i boleznei legkikh 2009; 2: 11-16.
14. Sun QF, Xu M, Wu JG, et al. Efficacy and safety of recombinant Mycobacterium tuberculosis ESAT-6 protein for diagnosis of pulmonary tuberculosis: a phase II trial. Med Sci Monit 2013; 19: 969-977.
15. Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J 2016; 47: 919-928.
16. Centers for Disease Control and Prevention. Extent and effects of recurrent shortages of purified-protein derivative tuberculin skin test antigen solutions-United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 1014-1015.
17. TB Diagnostics Market in Select High-Burden Countries: Current Market and Future Opportunities for Novel Diagnostics. http://unitaid.org/images/marketdynamics/publications/TB-Diagnostics-Market-in-Select-High-Burden- Countries-Current-Market-and-Future-Opportunities-for-Novel-Diagnostics.pdf Date last accessed: November 2, 2015. Date last updated: July 2015.
18. Hanson C, Sotgiu G, Loddenkemper R. Ensuring that the diagnosis of tuberculosis accelerates progress towards the Millennium Development Goals. Eur Respir J 2014; 44: 1-4.